Technical Trend Evolution and Price Movement
Anthem Biosciences currently trades at ₹755.35, slightly down by 0.62% from the previous close of ₹760.10. Despite this minor dip, the stock remains well above its 52-week low of ₹579.45 and retains a comfortable distance from its 52-week high of ₹873.25. The daily trading range today has been between ₹741.00 and ₹761.85, indicating some intraday volatility but overall resilience near the upper band.
The technical trend has improved from mildly bullish to bullish, signalling stronger price momentum. This is supported by the daily moving averages which are firmly bullish, suggesting that the short-term price action is aligned with an upward trajectory. The stock’s relative strength index (RSI) on the weekly and monthly charts currently shows no definitive signal, indicating that the stock is neither overbought nor oversold, leaving room for further price appreciation without immediate risk of a reversal.
MACD and Momentum Indicators
The Moving Average Convergence Divergence (MACD) indicator on the weekly chart is bullish, reinforcing the positive momentum. Although the monthly MACD does not provide a clear signal, the weekly bullish stance suggests that momentum is gaining strength in the near term. The KST (Know Sure Thing) indicator also aligns with this view, showing bullish signals on both weekly and monthly timeframes, which typically precedes sustained price moves.
Bollinger Bands on the weekly chart are mildly bullish, indicating that price volatility is contained within an upward trending channel. This technical setup often precedes a breakout or continuation of the current trend, providing a favourable environment for the stock to test higher levels.
Volume and Trend Confirmation
On-balance volume (OBV) readings on both weekly and monthly charts show no clear trend, suggesting that volume has not yet decisively confirmed the price movement. This could imply that while price momentum is improving, broader market participation remains cautious. The Dow Theory readings are mixed, with a mildly bearish signal on the weekly chart but a mildly bullish stance on the monthly chart, reflecting some short-term uncertainty amid a longer-term positive outlook.
Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.
- - Investment Committee approved
- - 50+ candidates screened
- - Strong post-announcement performance
Comparative Performance and Market Context
Anthem Biosciences has outperformed the broader Sensex index over key periods this year. Year-to-date, the stock has delivered a robust return of 16.02%, while the Sensex has declined by 12.85%. Over the past month and week, the stock’s returns were -0.58% and -1.25% respectively, both outperforming the Sensex’s sharper declines of -3.44% and -2.90% in the same periods. This relative strength highlights the stock’s resilience amid broader market weakness.
Longer-term comparisons show the Sensex outperforming over three, five, and ten-year horizons, but Anthem’s recent momentum and technical upgrades suggest it is gaining traction as a mid-cap contender within the Pharmaceuticals & Biotechnology sector.
Mojo Score Upgrade and Analyst Sentiment
MarketsMOJO has upgraded Anthem Biosciences’ Mojo Grade from Sell to Buy as of 21 May 2026, reflecting a significant improvement in the company’s technical and fundamental outlook. The current Mojo Score stands at a healthy 78.0, indicating strong buy signals based on a comprehensive assessment of price momentum, volume, and trend quality.
This upgrade is particularly notable given the mid-cap status of the company, which often entails higher volatility but also greater growth potential. The improved technical trend, combined with positive momentum indicators, supports a constructive view for investors seeking exposure to the Pharmaceuticals & Biotechnology sector.
Moving Averages and Short-Term Outlook
The daily moving averages are bullish, with the stock price trading above key averages such as the 50-day and 200-day moving averages. This alignment typically signals a continuation of upward momentum and reduces the likelihood of a near-term correction. Traders often view such a setup as a confirmation of strength, encouraging accumulation on dips.
However, the lack of a clear volume trend and mixed Dow Theory signals suggest that investors should remain vigilant for potential short-term volatility. The stock’s current trading range between ₹741.00 and ₹761.85 today reflects this cautious optimism.
Anthem Biosciences Ltd caught your attention? Explore our comprehensive research report with in-depth analysis of this mid-cap Pharmaceuticals & Biotechnology stock – fundamentals, valuations, financials, and technical outlook!
- - Comprehensive research report
- - In-depth mid-cap analysis
- - Valuation assessment included
Investor Takeaway and Strategic Considerations
For investors analysing Anthem Biosciences, the recent technical upgrades and bullish momentum indicators provide a compelling case for considering the stock as a buy candidate within the mid-cap Pharmaceuticals & Biotechnology space. The stock’s ability to outperform the Sensex year-to-date and maintain strength amid sector volatility underscores its potential as a growth-oriented investment.
Nonetheless, the absence of strong volume confirmation and mixed signals from Dow Theory warrant a measured approach. Investors should monitor key technical levels, including the 52-week high of ₹873.25 as a potential upside target, and the 50-day moving average as a support level. A sustained break above recent highs could trigger further bullish momentum, while a failure to hold support may signal consolidation or correction.
Overall, Anthem Biosciences’ technical profile has improved markedly, with the MarketsMOJO upgrade reinforcing confidence in the stock’s near-term prospects. This makes it an attractive option for investors seeking exposure to a mid-cap pharmaceutical player with improving momentum and a positive technical outlook.
Summary of Technical Signals
- Technical trend upgraded from mildly bullish to bullish
- Weekly MACD and KST indicators are bullish; monthly indicators neutral to mildly bullish
- Daily moving averages confirm bullish momentum
- RSI shows no overbought or oversold extremes, allowing room for further gains
- Bollinger Bands mildly bullish on weekly timeframe
- Dow Theory mixed signals: mildly bearish weekly, mildly bullish monthly
- OBV shows no clear volume trend, suggesting cautious participation
Investors should weigh these technical factors alongside fundamental analysis to make informed decisions in the evolving market environment.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
